Literature DB >> 25002745

Effect of CYP2A6 genetic polymorphism on the metabolic conversion of tegafur to 5-fluorouracil and its enantioselectivity.

Ikuo Yamamiya1, Kunihiro Yoshisue2, Yuji Ishii2, Hideyuki Yamada2, Masato Chiba2.   

Abstract

Tegafur (FT), a prodrug of 5-fluorouracil, is a chiral molecule, a racemate of R- and S-isomers, and CYP2A6 plays an important role in the enantioselective metabolism of FT in human liver microsomes (R-FT >> S-FT). This study examined the enantioselective metabolism of FT by microsomes prepared from Sf9 cells expressing wild-type CYP2A6 and its variants (CYP2A6*7, *8, *10, and *11) that are highly prevalent in the Asian population. We also investigated the metabolism of coumarin and nicotine, both CYP2A6 probe drugs, in these variants. Enzyme kinetic analyses showed that CYP2A6.7 (I471T) and CYP2A6.10 (I471T and R485L) had markedly lower Vmax values for both enantiomers than wild-type enzyme (CYP2A6.1) and other variant enzymes, whereas Km values were higher in most of the variant enzymes for both enantiomers than CYP2A6.1. The ratios of Vmax and Km values for R-FT to corresponding values for S-FT (R/S ratio) were similar among enzymes, indicating little difference in enantioselectivity among the wild-type and variant enzymes. Similarly, both CYP2A6.7 and CYP2A6.10 had markedly lower Vmax values for coumarin 7-hydroxylase and nicotine C-oxidase activities than CYP2A6.1 and other variant enzymes, whereas Km values were higher in most of the variant enzymes for both activities than CYP2A6.1. In conclusion, the amino acid substitutions in CYP2A6 variants generally resulted in lower affinity for substrates, while Vmax values were selectively reduced in CYP2A6.7 and CYP2A6.10. Consistent R/S ratios among CYP2A6.1 and variant enzymes indicated that the amino acid substitutions had little effect on enantioselectivity in the metabolism of FT.
Copyright © 2014 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25002745     DOI: 10.1124/dmd.114.058008

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  6 in total

1.  Phase I study of orally administered S-1 in combination with epirubicin and oxaliplatin in patients with advanced solid tumors and chemotherapy-naïve advanced or metastatic esophagogastric cancer.

Authors:  Markus Moehler; Rolf Mahlberg; Volker Heinemann; Radka Obermannová; Eugen Kubala; Bohuslav Melichar; Arndt Weinmann; Paul Scigalla; Marietta Tesařová; Petr Janda; Fabienne Hédouin-Biville; Wasat Mansoor
Journal:  Gastric Cancer       Date:  2016-06-02       Impact factor: 7.370

Review 2.  Genotypes Affecting the Pharmacokinetics of Anticancer Drugs.

Authors:  Daphne Bertholee; Jan Gerard Maring; André B P van Kuilenburg
Journal:  Clin Pharmacokinet       Date:  2017-04       Impact factor: 6.447

3.  Analyses of nicotine metabolism biomarker genetics stratified by sex in African and European Americans.

Authors:  Meghan J Chenoweth; Lisa Sanderson Cox; Nikki L Nollen; Jasjit S Ahluwalia; Neal L Benowitz; Caryn Lerman; Jo Knight; Rachel F Tyndale
Journal:  Sci Rep       Date:  2021-10-01       Impact factor: 4.379

Review 4.  A Systematic Review of Clinical Validated and Potential miRNA Markers Related to the Efficacy of Fluoropyrimidine Drugs.

Authors:  Xiaomeng Sun; Jiani Chen; Xintao Chen; Qianmin Gao; Wei Chen; Xun Zou; Feng Zhang; Shouhong Gao; Shi Qiu; Xiaoqiang Yue; Houshan Yao; Xuan Liu; Mingming Li
Journal:  Dis Markers       Date:  2022-08-23       Impact factor: 3.464

5.  Applicability of the Rayleigh equation for enantioselective metabolism of chiral xenobiotics by microsomes, hepatocytes and in-vivo retention in rabbit tissues.

Authors:  Shifra Jammer; Faina Gelman; Ovadia Lev
Journal:  Sci Rep       Date:  2016-03-29       Impact factor: 4.379

6.  Genome-wide association meta-analysis of nicotine metabolism and cigarette consumption measures in smokers of European descent.

Authors:  Jadwiga Buchwald; Meghan J Chenoweth; Teemu Palviainen; Gu Zhu; Christian Benner; Scott Gordon; Tellervo Korhonen; Samuli Ripatti; Pamela A F Madden; Terho Lehtimäki; Olli T Raitakari; Veikko Salomaa; Richard J Rose; Tony P George; Caryn Lerman; Matti Pirinen; Nicholas G Martin; Jaakko Kaprio; Anu Loukola; Rachel F Tyndale
Journal:  Mol Psychiatry       Date:  2020-03-10       Impact factor: 13.437

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.